From bench to bedside: evolving therapeutic targets in autoimmune blistering disease

• Published in: Journal of the European Academy of Dermatology and Venereology 2019-12, Vol.33 (12), p.2239-2252
• Main Authors: Kridin, K., Kowalski, E.H., Kneiber, D., Laufer‐Britva, R., Amber, K.T.
• Format: Article
• Language: English
• Subjects: Animals; Autoimmune Diseases - immunology; Autoimmune Diseases - therapy; Dermatologic Agents - therapeutic use; Evidence-Based Medicine; Humans; Mice; Skin Diseases, Vesiculobullous - immunology; Skin Diseases, Vesiculobullous - therapy; Translational Medical Research
• ISSN: 0926-9959; 1468-3083
• DOI: 10.1111/jdv.15816

Autoimmune blistering diseases comprise a group of heterogenous conditions characterized by the loss of tolerance and subsequent development of autoantibodies targeting epidermal and subepidermal adhesion proteins. Blisters and erosions form on the skin and mucous membranes leading to significant morbidity and mortality. Traditional therapies rely on systemic immunosuppression. Advancements in our understanding of the pathophysiology of pemphigus and pemphigoid have led to the development of molecules which target specific pathways involved in induction and perpetuation of disease. In this review, we outline the novel therapeutic strategies including B‐cell depletion, T‐regulatory cell repletion, cell signalling inhibitors and small molecular inhibitors, inhibitory monoclonal antibodies, as well as complement inhibition. We additionally review their current level of clinical evidence. We lastly review therapeutics targets gleaned from the experimental epidermolysis bullosa acquisita mouse model. These emerging treatments offer an exciting progression from basic science discoveries that have the potential to transform the treatment paradigm in autoimmune blistering diseases.